Age-related Macular Degeneration (AMD) Drugs Market Size, Share Detailed Report 2026 to 2035

Report Id: 2854 Pages: 172 Last Updated: 15 October 2024 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Age-related Macular Degeneration (AMD) Drugs Market :

Age-related Macular Degeneration (AMD) Drugs Market by Products -

  • Lucentis
  • Eylea & Eylea HD
  • Vabysmo
  • Syfovre
  • Other Products

age related macular

Age-related Macular Degeneration (AMD) Drugs Market by Molecules -

  • Ranibizumab
  • Aflibercept
  • Faricimab
  • Pegcetoplan
  • Other Molecules

Age-related Macular Degeneration (AMD) Drugs Market by Type of AMD -

  • Wet AMD
  • Dry AMD

Age-related Macular Degeneration (AMD) Drugs Market by Type of Approval type -

  • Biologic
  • Biosimilar

Age-related Macular Degeneration (AMD) Drugs Market by End User -

  • Hospitals
  • Specialty Centers
  • Long-Term Care Facilities

Age-related Macular Degeneration (AMD) Drugs Market by Region-

  • North America-
    • The US
    • Canada
  • Europe-
    • Germany
    • The UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific-
    • China
    • Japan
    • India
    • South Korea
    • South East Asia
    • Rest of Asia Pacific
  • Latin America-
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  •  Middle East & Africa-
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Chapter 1.          Methodology and Scope

1.1.        Research Methodology

1.2.        Research Scope & Assumptions

Chapter 2.          Executive Summary

Chapter 3.          Global Age-related Macular Degeneration (AMD) Drugs Market Snapshot

Chapter 4.          Global Age-related Macular Degeneration (AMD) Drugs Market Variables, Trends & Scope

4.1.        Market Segmentation & Scope

4.2.        Drivers

4.3.        Challenges

4.4.        Trends

4.5.        Investment and Funding Analysis

4.6.        Porter's Five Forces Analysis

4.7.        Incremental Opportunity Analysis (US$ MN), 2024-2031

4.8.        Global Age-related Macular Degeneration (AMD) Drugs Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031

4.9.        Competitive Landscape & Market Share Analysis, By Key Player (2023)

4.10.     Use/impact of AI on Age-related Macular Degeneration (AMD) Drugs Industry Trends

Chapter 5.          Age-related Macular Degeneration (AMD) Drugs Market Segmentation 1: By Products, Estimates & Trend Analysis

5.1.        Market Share by Products, 2023 & 2031

5.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Products:

5.2.1.    Lucentis

5.2.2.    Eylea & Eylea HD

5.2.3.    Vabysmo

5.2.4.    Syfovre

5.2.5.    Other Products

Chapter 6.          Age-related Macular Degeneration (AMD) Drugs Market Segmentation 2: By Molecules, Estimates & Trend Analysis

6.1.        Market Share by Molecules, 2023 & 2031

6.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Molecules:

6.2.1.    Ranibizumab

6.2.2.    Aflibercept

6.2.3.    Faricimab

6.2.4.    Pegcetoplan

6.2.5.    Other Molecules

Chapter 7.          Age-related Macular Degeneration (AMD) Drugs Market Segmentation 3: By Type of AMD, Estimates & Trend Analysis

7.1.        Market Share by Type of AMD, 2023 & 2031

7.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Type of AMD:

7.2.1.    Wet AMD

7.2.2.    Dry AMD

Chapter 8.          Age-related Macular Degeneration (AMD) Drugs Market Segmentation 4: By Approval type, Estimates & Trend Analysis

8.1.        Market Share by Approval type, 2023 & 2031

8.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Approval type:

8.2.1.    Biologic

8.2.2.    Biosimilar

Chapter 9.          Age-related Macular Degeneration (AMD) Drugs Market Segmentation 5: By End Users, Estimates & Trend Analysis

9.1.        Market Share by End Users, 2023 & 2031

9.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End Users:

9.2.1.    Hospitals

9.2.2.    Specialty Centers

9.2.3.    Long-Term Care Facilities

Chapter 10.        Age-related Macular Degeneration (AMD) Drugs Market Segmentation 6: Regional Estimates & Trend Analysis

10.1.     Global Age-related Macular Degeneration (AMD) Drugs Market, Regional Snapshot 2023 & 2031

10.2.     North America

10.2.1.  North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

10.2.1.1.             US

10.2.1.2.             Canada

10.2.2.  North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2024-2031

10.2.3.  North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2024-2031

10.2.4.  North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2024-2031

10.2.5.  North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Approval type, 2024-2031

10.2.6.  North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2024-2031

10.3.     Europe

10.3.1.  Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

10.3.1.1.             Germany

10.3.1.2.             U.K.

10.3.1.3.             France

10.3.1.4.             Italy

10.3.1.5.             Spain

10.3.1.6.             Rest of Europe

10.3.2.  Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2024-2031

10.3.3.  Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2024-2031

10.3.4.  Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2024-2031

10.3.5.  Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Approval type, 2024-2031

10.3.6.  Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2024-2031

10.4.     Asia Pacific

10.4.1.  Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

10.4.1.1.             India

10.4.1.2.             China

10.4.1.3.             Japan

10.4.1.4.             Australia

10.4.1.5.             South Korea

10.4.1.6.             Hong Kong

10.4.1.7.             Southeast Asia

10.4.1.8.             Rest of Asia Pacific

10.4.2.  Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2024-2031

10.4.3.  Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2024-2031

10.4.4.  Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2024-2031

10.4.5.  Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts By Approval type, 2024-2031

10.4.6.  Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts By End Users, 2024-2031

10.5.     Latin America

10.5.1.  Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

10.5.1.1.             Brazil

10.5.1.2.             Mexico

10.5.1.3.             Rest of Latin America

10.5.2.  Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2024-2031

10.5.3.  Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2024-2031

10.5.4.  Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2024-2031

10.5.5.  Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Approval type, 2024-2031

10.5.6.  Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2024-2031

10.6.     Middle East & Africa

10.6.1.  Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

10.6.1.1.             GCC Countries

10.6.1.2.             Israel

10.6.1.3.             South Africa

10.6.1.4.             Rest of Middle East and Africa

10.6.2.  Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2024-2031

10.6.3.  Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2024-2031

10.6.4.  Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2024-2031

10.6.5.  Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Approval type, 2024-2031

10.6.6.  Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2024-2031

Chapter 11.        Competitive Landscape

11.1.     Major Mergers and Acquisitions/Strategic Alliances

11.2.     Company Profiles

11.2.1.  Regeneron Pharmaceuticals Inc. (US)

11.2.1.1.             Business Overview

11.2.1.2.             Key Product/Service Offerings

11.2.1.3.             Financial Performance

11.2.1.4.             Geographical Presence

11.2.1.5.             Recent Developments with Business Strategy

11.2.2.  Bayer AG (Germany)

11.2.3.  F. Hoffmann-La Roche AG (Switzerland)

11.2.4.  Novartis AG (Switzerland)

11.2.5.  Apellis Pharmaceuticals, Inc. (US)

11.2.6.  Coherus BioSciences, Inc. (US)

11.2.7.  Astellas Pharma Inc. (Japan)

11.2.8.  Biogen (US)

11.2.9.  STADA Arzneimittel AG  (Germany)

11.2.10.              Formycon AG (Germany)

11.2.11.              Biocon. (India)

11.2.12.              Outlook Therapeutics, Inc. (US)

11.2.13.              Intas Pharmaceuticals Ltd. (India)

11.2.14.              Teva Pharmaceutical Industries Ltd. (Israel)

11.2.15.              Chengdu Kanghong Biotech Company (China)

11.2.16.              Sandoz Group AG (Switzerland)

11.2.17.              Stealth BioTherapeutics Inc.  (US)

11.2.18.              Ocular Therapeutix, Inc. (US)

11.2.19.              Opthea Limited, Inc. (Australia)

11.2.20.              Kodiak Sciences Inc. (US)

11.2.21.              Innovent Biologics, Inc. (China)

11.2.22.              Bio-Thera Solution Inc. (China)

11.2.23.              Alvotech (Iceland)

11.2.24.              Alteogen Inc. (South Korea)

11.2.25.              Shanghai Henlius Biotech, Inc. (China)

11.2.26.              Amgen Inc. (US)

11.2.27.              Ocumension Therapeutics. (China)

11.2.28.              Adverum Biotechnologies, Inc. (US)

11.2.29.              Other Prominent Players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
6149
Security Code field cannot be blank!

Frequently Asked Questions

Age-related Macular Degeneration (AMD) Drugs Market Size is valued at USD 9.58 Bn in 2023 and is predicted to reach USD 19.77 Bn by the year 2031

Age-related Macular Degeneration (AMD) Drugs Market is expected to grow at an 9.7% CAGR during the forecast period for 2024-2031.

Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche AG (Switzerland), Novartis AG (Switzerland), Apellis Pharmaceuticals, In

The Age-related Macular Degeneration (AMD) Drugs Market includes five segments Products, Molecules, Type of AMD, Approval type, and End-User.

North American region is leading the Age-related Macular Degeneration (AMD) Drugs Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying